[Federal Register Volume 63, Number 90 (Monday, May 11, 1998)]
[Notices]
[Page 25863]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-12235]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee (CLIAC): 
Meeting

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meetings.

    Name: Workgroup on Genetic Testing, Clinical Laboratory 
Improvement Advisory Committee.
    Times and Dates: 8:30 a.m.-5 p.m., May 27, 1998; 8 a.m.-10 a.m., 
May 28, 1998.
    Place: CDC, Auditorium B, Building 2, 1600 Clifton Road, NE, 
Atlanta, Georgia 30333.
    Status: Open to the public, limited only by the space available. 
The room will accommodate approximately 150 people.
    Purpose: This Workgroup advises CLIAC on issues related to 
Genetic Testing.
    Matters To Be Discussed: The Workgroup will review and discuss 
the Clinical Laboratory Improvement Amendments (CLIA) regulations 
and general or specific CLIA requirements that apply to pre-
analytic, analytic, and post-analytic components of genetic testing.
    Agenda items are subject to change as priorities dictate.

    Name: Clinical Laboratory Improvement Advisory Committee.
    Times and Dates: 10:30 a.m.-5 p.m., May 28, 1998; 8:30 a.m.-5 
p.m., May 29, 1998.
    Place: CDC, Auditorium B, Building 2, 1600 Clifton Road, NE, 
Atlanta, Georgia 30333.
    Status: Open to the public, limited only by the space available. 
The meeting room will accommodate approximately 150 people.
    Purpose: This committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services, the Assistant Secretary for Health, and the Director, CDC, 
regarding the need for, and the nature of, revisions to the 
standards Page 3 under which clinical laboratories are regulated; 
the impact of proposed revisions to the standards; and the 
modification of the standards to accommodate technological advances.
    Matters To Be Discussed: The agenda will include an update on 
CLIA implementation; general or specific CLIA requirements that 
apply to pre-analytic, analytic, and post-analytic components of 
genetic testing; and the applicability of CLIA to laboratory testing 
performed for assisted reproductive technology (ART).
    The Committee solicits oral and written testimony on the 
application of CLIA regulations and ART. Requests to make an oral 
presentation should be submitted in writing to the contact person 
listed below by close of business, May 22, 1998. All requests to 
make oral comments should contain the name, address, telephone 
number, and organizational affiliation of the presenter. Written 
comments should not exceed five single-spaced, typed pages in length 
and should be received by the contact person listed below by close 
of business, May 22, 1998.
    Agenda items are subject to change as priorities dictate.
    Contact Person for Additional Information: John C. Ridderhof, 
Dr.P.H., Division of Laboratory Systems, Public Health Practice 
Program Office, CDC, 4770 Buford Highway, NE, Mailstop G-25, 
Atlanta, Georgia 30341-3724, telephone 770/488-8076, FAX 770/488-
1129.

    Dated: April 30, 1998.
Julia M. Fuller,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 98-12235 Filed 5-8-98; 8:45 am]
BILLING CODE 4163-18-P